^
    3d
    Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets (clinicaltrials.gov)
    P1, N=18, Recruiting, Hutchmed
    New P1 trial
    |
    sovleplenib (HMPL-523)
    11d
    Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans (clinicaltrials.gov)
    P1, N=54, Recruiting, Hutchmed
    New P1 trial
    |
    sovleplenib (HMPL-523)
    11d
    MiR-31 suppresses lung adenocarcinoma cell proliferation through CDK1 and E2F2-mediated cell cycle arrest. (PubMed, Discov Oncol)
    Collectively, our study establishes miR-31 as a novel biomarker for LUAD proliferative potential and implicates the miR-31/CDK1-E2F2 network as a promising target for disrupting LUAD progression. These findings establish a miRNA-centric precision therapeutic paradigm for effectively suppressing oncogenic proliferation in LUAD.
    Journal
    |
    EGF (Epidermal growth factor) • CDK1 (Cyclin-dependent kinase 1) • MIR31 (MicroRNA 31) • E2F2 (E2F Transcription Factor 2)
    |
    Tavalisse (fostamatinib)
    12d
    The small-molecule Syk inhibitor R788 inhibits hematopoiesis and worsens anemia in sickle cell disease mice. (PubMed, Blood Vessel Thromb Hemost)
    Severe anemia and neutropenia induced by R788 in the sickle mouse model suggests that concomitant use of Syk inhibitors with hydroxyurea in patients with SCD should be approached cautiously. Further research is required to clarify the benefits and risks of selective Syk inhibition in SCD and other hemolytic conditions exhibiting stress hematopoiesis.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase)
    |
    hydroxyurea • Tavalisse (fostamatinib)
    1m
    Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. (PubMed, Mol Ther Oncol)
    Additionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not. Our data suggest that fostamatinib may be repurposed as an effective drug that enhances OV therapy in PDAC by promoting OV replication and suppressing tumor growth.
    Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    2ms
    Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=1, Terminated, National Heart, Lung, and Blood Institute (NHLBI) | Completed --> Terminated; Clinical trial was halted prematurely due to low enrollment
    Trial termination
    |
    Tavalisse (fostamatinib)
    2ms
    Inflammatory Signal Inhibitors for COVID-19 (MATIS) (clinicaltrials.gov)
    P1/2, N=185, Completed, Imperial College London | Recruiting --> Completed | N=456 --> 185
    Trial completion • Enrollment change
    |
    CRP (C-reactive protein)
    |
    Jakafi (ruxolitinib) • Tavalisse (fostamatinib)
    2ms
    Network Controllability Reveals Key Mitigation Points for Tumor-Promoting Signaling in Tumor-Educated Platelets. (PubMed, Int J Mol Sci)
    A low-dose combination therapy of fostamatinib, Aducanumab, and acetylsalicylic acid (aspirin) may control TEP effects. In conclusion, our preclinical in silico approach revealed FDA-approved drugs that allow therapeutic targeting of metastasis-promoting TEPs and target NSCLC at the same time.
    Journal
    |
    SYK (Spleen tyrosine kinase) • FCGR2A (Fc fragment of IgG receptor IIa) • ITGA2B (Integrin Subunit Alpha 2b)
    |
    Tavalisse (fostamatinib) • aspirin
    2ms
    Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=0, Withdrawn, National Heart, Lung, and Blood Institute (NHLBI) | N=20 --> 0 | Trial completion date: Dec 2028 --> Nov 2025 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Dec 2028 --> Nov 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Tavalisse (fostamatinib)
    3ms
    Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias (clinicaltrials.gov)
    P2, N=1, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Completed | N=20 --> 1 | Trial completion date: Apr 2026 --> Oct 2025 | Trial primary completion date: Apr 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tavalisse (fostamatinib)
    4ms
    2018-523-00US1: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma (clinicaltrials.gov)
    P1, N=87, Terminated, Hutchmed | N=140 --> 87 | Trial completion date: Jan 2026 --> Mar 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2025; Study terminated by sponsor
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    sovleplenib (HMPL-523)
    4ms
    The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=0, Withdrawn, Hutchmed | N=48 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    sovleplenib (HMPL-523)